Receive our newsletter – data, insights and analysis delivered to you
June 11, 2009

Emergent’s BioThrax Anthrax Vaccine Gets Longer Shelf Life

Emergent BioSolutions has received FDA approval to extend the shelf life of BioThrax (Anthrax Vaccine Adsorbed) from three to four years. Based on the approval, Emergent will receive a payment of approximately $30m for doses previously delivered to the strategic national stockpile (SNS) u

By cms admin

Emergent BioSolutions has received FDA approval to extend the shelf life of BioThrax (Anthrax Vaccine Adsorbed) from three to four years.

Based on the approval, Emergent will receive a payment of approximately $30m for doses previously delivered to the strategic national stockpile (SNS) under the terms of the company’s BioThrax procurement contract with the US Department of Health and Human Services.

In addition, the approval has resulted in an immediate price increase for the future delivery of BioThrax doses valued at $405m, for the delivery of 14.5 million doses.

Emergent chairman and CEO Fuad El-Hibri said that the contract extension was important as it would extend the ability of the US Government to store the product in the SNS.

“We are continuing our efforts to further enhance the attributes of BioThrax, including research towards a further reduction in the vaccination schedule and an expanded label indication for post-exposure prophylaxis. We believe these enhancements, if approved, will advance the US government’s preparedness efforts in response to anthrax as a potential weapon of bioterrorism,” El-Hibri said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU